ARD1A Antibody (Rabbit mAb) [A24F7] Datasheet

Biological Description

Specificity	ARD1A Antibody (Rabbit mAb) [A24F7] detects endogenous levels of total ARD1A protein.
Background	ARD1A, also known as NAA10 (hARD1), is a protein acetyltransferase and the catalytic subunit of the major human N-terminal acetyltransferase. Mouse ARD1 is the only known protein acetyltransferase that acetylates both the α-amino group at the protein N-terminus and the ε-amino groups of lysine side chains. Human ARD1 forms a stable complex with NATH, the human counterpart of yeast Nat1p, mirroring the yeast Ard1p–Nat1p N-acetyltransferase. The ARD1–NATH complex has N-terminal acetylation activity, and both subunits bind ribosomal subunits, which places acetylation alongside protein synthesis. NATH stays in the cytoplasm, while ARD1 is found in both the cytoplasm and the nucleus. ARD1 partly co-localizes with the transcription factor HIF-1α, an ε-amino substrate of ARD1. Endogenous ARD1 and NATH are expressed in epithelial, glioma and promyelocytic cell lines. Both proteins are cleaved during apoptosis, which lowers N-terminal acetyltransferase activity. A missense variant in NAA10 (p.Ser37Pro) causes a lethal X-linked disorder of male infants, also called Ogden syndrome. It is marked by an aged appearance, craniofacial anomalies, low muscle tone, global developmental delay, undescended testes and cardiac arrhythmias. The variant was found independently in two unrelated families, sits in a conserved region and is absent from controls. The mutant enzyme has markedly impaired activity, making this a human genetic disorder caused by direct loss of N-terminal acetylation.

Specificity

ARD1A Antibody (Rabbit mAb) [A24F7] detects endogenous levels of total ARD1A protein.

Background

ARD1A, also known as NAA10 (hARD1), is a protein acetyltransferase and the catalytic subunit of the major human N-terminal acetyltransferase. Mouse ARD1 is the only known protein acetyltransferase that acetylates both the α-amino group at the protein N-terminus and the ε-amino groups of lysine side chains. Human ARD1 forms a stable complex with NATH, the human counterpart of yeast Nat1p, mirroring the yeast Ard1p–Nat1p N-acetyltransferase. The ARD1–NATH complex has N-terminal acetylation activity, and both subunits bind ribosomal subunits, which places acetylation alongside protein synthesis. NATH stays in the cytoplasm, while ARD1 is found in both the cytoplasm and the nucleus. ARD1 partly co-localizes with the transcription factor HIF-1α, an ε-amino substrate of ARD1. Endogenous ARD1 and NATH are expressed in epithelial, glioma and promyelocytic cell lines. Both proteins are cleaved during apoptosis, which lowers N-terminal acetyltransferase activity. A missense variant in NAA10 (p.Ser37Pro) causes a lethal X-linked disorder of male infants, also called Ogden syndrome. It is marked by an aged appearance, craniofacial anomalies, low muscle tone, global developmental delay, undescended testes and cardiac arrhythmias. The variant was found independently in two unrelated families, sits in a conserved region and is absent from controls. The mutant enzyme has markedly impaired activity, making this a human genetic disorder caused by direct loss of N-terminal acetylation.

Usage Information

Application

WB, IP

Dilution

WB	IP
1:1000	1:50

Reactivity

Human, Mouse, Rat, Monkey

Source

Rabbit Monoclonal Antibody

MW

26 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/15496142/
https://pubmed.ncbi.nlm.nih.gov/21700266/

ARD1A Antibody (Rabbit mAb) [A24F7]

Biological Description

Usage Information

References

Application Data